Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4875685 | 0.98 | NR1H3 (0.60) | NR1H3KMT2AMEN1PPARAPPARD | |
| SCHEMBL9480783 | 0.84 | NR1H3 (0.66) | NR1H3KMT2AMEN1PPARAPPARD | |
| SCHEMBL4649471 | 0.83 | KMT2A (0.78) | NR1H3KMT2AMEN1PPARAPPARD | |
| SCHEMBL30758581 | 0.81 | NR1H3 (0.62) | NR1H3KMT2AMEN1PPARAPPARD | |
| SCHEMBL13412864 | 0.81 | NR1H3 (0.62) | NR1H3KMT2AMEN1PPARAPPARD | |
| SCHEMBL7329212 | 0.81 | KMT2A (0.63) | NR1H3KMT2AMEN1PPARAPPARD | |
| SCHEMBL2688855 | 0.81 | NR1H3 (0.62) | NR1H3KMT2AMEN1PPARAPPARD | |
| SCHEMBL28302934 | 0.80 | CA9 (0.57) | NR1H3KMT2AMEN1CA9CA12 | |
| SCHEMBL9454327 | 0.80 | NR1H3 (0.71) | NR1H3KMT2AMEN1SCN2AGAA | |
| SCHEMBL12076522 | 0.78 | NR1H3 (0.73) | NR1H3KMT2AMEN1PPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1874733-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111346-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2006-10-26 | — | — | WO | disclosed |
| EP-0526488-B1 | BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS | PFIZER (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5326905-A | Benzylphosphonic acid tyrosine kinase inhibitors | PFIZER INC. (US) | 1994-07-05 | — | — | US | disclosed |
| EP-0526488-A1 | BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS. | PFIZER (US) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991015495-A1 | BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | TRPV1, TRPA1, P2RX3 | NR1H3 1628/4885KMT2A 4782/4885MEN1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.